CN104994860A - 用于治疗医院性肺炎的组合疗法 - Google Patents
用于治疗医院性肺炎的组合疗法 Download PDFInfo
- Publication number
- CN104994860A CN104994860A CN201480007538.3A CN201480007538A CN104994860A CN 104994860 A CN104994860 A CN 104994860A CN 201480007538 A CN201480007538 A CN 201480007538A CN 104994860 A CN104994860 A CN 104994860A
- Authority
- CN
- China
- Prior art keywords
- ceftazidime
- administration
- combination
- wei batan
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims (37)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910679229.5A CN110302203A (zh) | 2013-02-06 | 2014-02-06 | 用于治疗医院性肺炎的组合疗法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361761369P | 2013-02-06 | 2013-02-06 | |
US61/761369 | 2013-02-06 | ||
PCT/GB2014/050354 WO2014122468A1 (en) | 2013-02-06 | 2014-02-06 | Combination therapy for the treatment of nosocomial pneumonia |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910679229.5A Division CN110302203A (zh) | 2013-02-06 | 2014-02-06 | 用于治疗医院性肺炎的组合疗法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104994860A true CN104994860A (zh) | 2015-10-21 |
Family
ID=50114393
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480007538.3A Pending CN104994860A (zh) | 2013-02-06 | 2014-02-06 | 用于治疗医院性肺炎的组合疗法 |
CN201910679229.5A Pending CN110302203A (zh) | 2013-02-06 | 2014-02-06 | 用于治疗医院性肺炎的组合疗法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910679229.5A Pending CN110302203A (zh) | 2013-02-06 | 2014-02-06 | 用于治疗医院性肺炎的组合疗法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20150374673A1 (zh) |
EP (1) | EP2953626A1 (zh) |
JP (1) | JP6383367B2 (zh) |
KR (1) | KR20150115761A (zh) |
CN (2) | CN104994860A (zh) |
AU (1) | AU2014213795B2 (zh) |
BR (1) | BR112015018360B1 (zh) |
CA (1) | CA2897446A1 (zh) |
CL (1) | CL2015002180A1 (zh) |
MX (1) | MX2015010077A (zh) |
RU (1) | RU2684112C2 (zh) |
UA (1) | UA115683C2 (zh) |
WO (1) | WO2014122468A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109310682A (zh) * | 2016-06-17 | 2019-02-05 | 沃克哈特有限公司 | 抗菌组合物 |
CN113413367A (zh) * | 2021-08-16 | 2021-09-21 | 浙江尖峰药业有限公司 | 一种注射用阿维巴坦头孢甲肟复方粉针及其制备方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE044061T2 (hu) * | 2014-11-17 | 2019-09-30 | Entasis Therapeutics Ltd | Kombinációs terápia rezisztens bakteriális fertõzések kezelésére |
TW201639853A (zh) * | 2015-03-31 | 2016-11-16 | 木塔比利斯公司 | 雜環化合物及其於預防或治療細菌感染之用途 |
MX2017013792A (es) | 2015-09-16 | 2018-07-06 | Xuanzhu Pharma Co Ltd | INHIBIDORES DE íŸ-LACTAMASA Y USOS DE LOS MISMOS. |
PL3512851T3 (pl) | 2016-09-16 | 2022-11-14 | Entasis Therapeutics Limited | Związki stanowiące inhibitory beta-laktamazy |
US10434089B2 (en) | 2017-01-25 | 2019-10-08 | The Johns Hopkins University | Avibactam and carbapenems antibacterial agents |
EA038393B1 (ru) | 2017-05-08 | 2021-08-20 | Энтасис Терапеутикс, Инк. | Соединения и способы для лечения бактериальных инфекций |
US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
RU2746833C1 (ru) * | 2020-08-03 | 2021-04-21 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ | Способ моделирования экспериментального воспаления легких у крыс |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008524204A (ja) * | 2004-12-17 | 2008-07-10 | ヴィーナス・レメディーズ・リミテッド | 感染の処置に全面的解決を与えるための抗生物質の組合せ |
CN101074235B (zh) * | 2006-05-15 | 2010-05-12 | 中国药品生物制品检定所 | 头孢硫脒醇水化合物及其制备方法 |
CN101245080A (zh) * | 2007-02-14 | 2008-08-20 | 山东轩竹医药科技有限公司 | 含有吡唑并三唑的头孢菌素衍生物 |
CA2754677A1 (en) * | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis |
-
2014
- 2014-02-06 CA CA2897446A patent/CA2897446A1/en not_active Abandoned
- 2014-02-06 CN CN201480007538.3A patent/CN104994860A/zh active Pending
- 2014-02-06 UA UAA201507554A patent/UA115683C2/uk unknown
- 2014-02-06 AU AU2014213795A patent/AU2014213795B2/en active Active
- 2014-02-06 EP EP14704881.3A patent/EP2953626A1/en not_active Withdrawn
- 2014-02-06 BR BR112015018360-3A patent/BR112015018360B1/pt active IP Right Grant
- 2014-02-06 RU RU2015132369A patent/RU2684112C2/ru active
- 2014-02-06 KR KR1020157020951A patent/KR20150115761A/ko not_active Application Discontinuation
- 2014-02-06 JP JP2015556566A patent/JP6383367B2/ja active Active
- 2014-02-06 MX MX2015010077A patent/MX2015010077A/es unknown
- 2014-02-06 US US14/765,606 patent/US20150374673A1/en not_active Abandoned
- 2014-02-06 CN CN201910679229.5A patent/CN110302203A/zh active Pending
- 2014-02-06 WO PCT/GB2014/050354 patent/WO2014122468A1/en active Application Filing
-
2015
- 2015-08-05 CL CL2015002180A patent/CL2015002180A1/es unknown
Non-Patent Citations (5)
Title |
---|
ALAIN BONNEFOY等: "In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor", 《JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY》 * |
FRANCOISE BRESSOLLE等: "Endotracheal and Aerosol Administrations of Ceftazidime in Patients with Nosocomial Pneumonia: Pharmacokinetics and Absolute Bioavailability", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 * |
LORENTE L.等: "Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: A retrospective, nonrandomized, open-label, historical chart review", 《CLINICAL THERAPEUTICS》 * |
PREMAVATHY LEVASSEUR等: "In vitro antibacterial activity of the ceftazidime-avibactam(NXL104) combination against pseudomonas aeruginosa clinical isolates", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 * |
SARAH M. DRAWZ等: "Three decades of β-lactamase inhibitors", 《CLINICAL MICROBIOLOGY REVIEWS》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109310682A (zh) * | 2016-06-17 | 2019-02-05 | 沃克哈特有限公司 | 抗菌组合物 |
CN113413367A (zh) * | 2021-08-16 | 2021-09-21 | 浙江尖峰药业有限公司 | 一种注射用阿维巴坦头孢甲肟复方粉针及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20150115761A (ko) | 2015-10-14 |
AU2014213795B2 (en) | 2016-10-13 |
UA115683C2 (uk) | 2017-12-11 |
JP2016507547A (ja) | 2016-03-10 |
CL2015002180A1 (es) | 2015-11-27 |
JP6383367B2 (ja) | 2018-08-29 |
BR112015018360B1 (pt) | 2022-03-22 |
CA2897446A1 (en) | 2014-08-14 |
RU2684112C2 (ru) | 2019-04-04 |
CN110302203A (zh) | 2019-10-08 |
RU2015132369A (ru) | 2017-03-13 |
EP2953626A1 (en) | 2015-12-16 |
AU2014213795A1 (en) | 2015-07-30 |
US20150374673A1 (en) | 2015-12-31 |
MX2015010077A (es) | 2016-01-25 |
WO2014122468A1 (en) | 2014-08-14 |
BR112015018360A2 (pt) | 2017-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104994860A (zh) | 用于治疗医院性肺炎的组合疗法 | |
CN107108624A (zh) | 用于治疗耐药性细菌感染的组合疗法 | |
Giancola et al. | Assessment of fosfomycin for complicated or multidrug-resistant urinary tract infections: patient characteristics and outcomes | |
CN105392485A (zh) | 头孢特咯瓒抗生素组合物 | |
CN111346103A (zh) | 一种药物组合物及其应用 | |
CN110974814A (zh) | 双硫仑在细菌感染疾病中的潜在应用 | |
Molloy et al. | Infectious diseases pharmacotherapy for children with cystic fibrosis | |
JP2018526455A (ja) | 抗生物質療法 | |
Koomanachai et al. | Application of pharmacodynamic profiling for the selection of optimal β-lactam regimens in a large university hospital | |
Raman et al. | An interesting case of Empedobacter brevis bacteremia after right knee cellulitis | |
CN102781451A (zh) | 使用头孢洛林用于治疗细菌感染的组合物和方法 | |
Ito et al. | Potent antibacterial activities of latamoxef (moxalactam) against ESBL producing Enterobacteriaceae analyzed by Monte Carlo simulation | |
CN105616414B (zh) | 一种氧代哌嗪酰胺类化合物的新用途 | |
Asfour et al. | Successful treatment of Staphylococcus haemolyticus endocarditis in extremely premature baby with daptomycin | |
DeRyke et al. | Is all free time above the minimum inhibitory concentration the same: implications for β-lactam in vivo modelling | |
Roberts et al. | 652: IMPACT OF ANTIBIOTIC INITIATION SEQUENCE ON OUTCOMES IN PATIENTS WITH SEPTIC SHOCK | |
Chudzik-Rzad et al. | Overview on fosfomycin and its current and future clinical significance | |
US20210100787A1 (en) | Diiodohydroxyquinoline for the treatment of clostridium difficile infection | |
Ahmed et al. | Effect of Intensive Atropine Doses (Rapid Incremental Loading and Titration) for Management of Organophosphorus Pesticide Poisoning: a Case Series | |
Yuliandra | Targeting Bacterial Resistance: Rational Design and Evaluation of Antibiotic Combinations with Adjuvants | |
Bailing et al. | Mechanism of Colistin Resistance to Acinetobacter Baumannii and its Progress-A Review Article | |
Abed et al. | Antimicrobial Resistance Pattern of Pseudomonas aeruginosa Isolated from Burns and Wounds Infections in Hospitals of Baghdad | |
Kokai-Kun et al. | 1337. SYN-004 (Ribaxamase) Protects the Gut Microbiome of Patients Treated With Ceftriaxone From Disruption and Reduces the Emergence of Antimicrobial Resistance | |
Khawaja et al. | NEONATE WITH PNEUMONIA CAUSED BY BURKHOLDERIA CEPACIA COMPLEX–A STITCH IN TIME | |
US20220296639A1 (en) | Silver-/gold-compounds and methods thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: S. Darth Inventor after: Li Jianguo Inventor after: Mouton J.W. Inventor after: W. Nichols Inventor before: S. Darth Inventor before: J.Li Inventor before: Mouton J.W. Inventor before: W. Nichols |
|
COR | Change of bibliographic data | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: Sollentuna, Sweden Applicant after: AstraZeneca AB Address before: Sollentuna, Sweden Applicant before: Ashley Connan Tellier first Ltd. |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170721 Address after: Sollentuna, Sweden Applicant after: Ashley Connan Tellier first Ltd. Address before: Swedish Sodertalje Applicant before: ASTRAZENECA AB |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151021 |
|
RJ01 | Rejection of invention patent application after publication |